source
- Shionogi agrees $2 billion upfront purchase of IntraBio, adding oral rare-disease drug Aqneursa to its portfolioShionogi announced it will acquire Austin-based biotech IntraBio for $2 billion paid upfront. The deal brings IntraBio’s oral therapy Aqneursa into Shionogi’s rare‑disease pipeline, expanding its…
- Nobel-winning optogenetics opens path to experimental therapies for blindness and Alzheimer’sOptogenetics, a technique that uses light to control neurons, earned a 2026 Nobel Prize. Researchers say the method is transforming brain mapping from a simple roadmap to a detailed, three-dimensi…